Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.51 |
| ▸ | RELA | Q04206 | 4/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15235424 | 0.85 | NOTUM (0.55) | NR1H4NOTUMRAB9ANPC1NFKB1 | |
| SCHEMBL13271394 | 0.83 | NPC1 (0.61) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL31375602 | 0.83 | NPC1 (0.54) | NR1H4RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL14349374 | 0.82 | NR1H4 (0.50) | NR1H4NOTUMRAB9ANPC1NFKB1 | |
| SCHEMBL23917850 | 0.81 | NR1H4 (0.56) | NR1H4NOTUMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6497959 | 0.81 | AOC3 (0.50) | NOTUMRAB9ANPC1S1PR1MAPT | |
| SCHEMBL21889831 | 0.81 | AOC3 (0.50) | RAB9ANPC1NFKB1NFKB2RELA | |
| SCHEMBL5648596 | 0.81 | NR1H4 (0.54) | NR1H4RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL29277446 | 0.81 | AOC3 (0.44) | RAB9ANPC1S1PR1MAPTL3MBTL1 | |
| SCHEMBL14349556 | 0.81 | CHRNB2 (0.63) | RAB9ANPC1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | SENDA BIOSCIENCES, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | SAIL BIOMEDICINES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | SAIL BIOMEDICINES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1458392-B9 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| EP-1458392-B1 | ACRIDONES AS INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20090192196-A1 | Fungicide hydroximoyl-tetrazole derivatives | BAYER CROPSCIENCE AG (DE) | 2009-07-30 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7202381-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | NR1H4 126/4885NOTUM 4658/4885RAB9A 3552/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | NR1H4 113/4885NOTUM 4383/4885RAB9A 4428/4885 |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | AHR, ARNT, AIPL1 | NR1H4 89/4885NOTUM 4745/4885RAB9A 3800/4885 |
| US-20090192196-A1 | Fungicide hydroximoyl-tetrazole derivatives | HAAO, HAO1, CYP51A1 | NR1H4 4588/4885NOTUM 937/4885RAB9A 3465/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | NR1H4 4508/4885NOTUM 3492/4885RAB9A 361/4885 |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | NR1H4 2784/4885NOTUM 25/4885RAB9A 1883/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | NR1H4 487/4885NOTUM 1295/4885RAB9A 2014/4885 |
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | MYC, MYCBP, MAX | NR1H4 4656/4885NOTUM 4142/4885RAB9A 2681/4885 |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | AHR, ARNT, AIPL1 | NR1H4 42/4885NOTUM 4611/4885RAB9A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.